Aggressive Lymphoma Workshop

Bologna, Royal Hotel Carlton May 8-9, 2023

President: Pier Luigi Zinzani



ALMA MATER STUDIORUM UNIVERSITÀ DI BOLOGNA Dipartimento di Scienze mediche e chirurgiche

SERVIZIO SANITARIO REGIONALE EMILIA-ROMAGNA Azienda Ospedaliero - Universitaria di Bologna Aggressive Lymphoma Workshop

Bologna, Royal Hotel Carlton, May 8-9, 2023

Use of Mosunetuzumab in Aggressive B Cell Lymphoma

Elizabeth Budde, M.D., Ph.D.

City of Hope National Cancer Center

Aggressive Lymphoma Workshop

Disclosures

Disclosures of Name Surname

Company name	Research support	Employee	Consultant	Stockholder	Speakers bureau	Advisory board	Other
AstraZeneca	x					x	
Amgen	x						
ADC Therapeutics						x	
Roche			x			x	
Merck	x						
Mustang Therapeutics	x						
Abbive						x	
Gilead						x	
Nurix						x	


Mosunetuzumab: a bispecific antibody targeting CD3 and CD20


• Full-length humanized IgG1 antibody

- Longer half-life than fragment-based drug formats
- PK properties enable once weekly to q3w dosing
- Does not require *ex-vivo* T-cell manipulation
- Off the shelf, readily available treatment



- Redirects T-cells to engage and eliminate malignant B-cells
- Conditional agonist: T-cell activation dependent on Bcell engagement
- Amino-acid substitution (N297G) to inactivate ADCC and avoid destruction of engaged T cells





ADCC, antibody-dependent cell-mediated cytotoxicity

Sun et al. Sci Transl Med 2015

GO29781: study design

Open-label, multicenter Phase I/lb study in R/R B-cell NHL patients (NCT02500407)

<u>Group A (n=33)</u>	<u>Group B (n=270)</u>
Fixed dosing on D1 of each 21-day cycle	Step-up dosing during Cycle 7 Fixed dosing on D1 of each 21-day cycle thereafter
2.8mg 0.05mg	1/2/60mg → 0.4/1/2.8mg
D1 D1 D1 Cycle 1 Cycle 2 Cycle 3 ••••	D1 D8 D15 D1 D1 Cycle 1 Cycle 2 Cycle 3 21 days

Primary objectives

- Safety, tolerability, MTD, best objective response (per Cheson 2007 criteria¹)
 - Safety: C1D1/D8/D15 dose levels: 0.4/1.0/2.8 1.0/2.0/60.0 mg
 - Efficacy: C1D1/D8/D15 dose levels: 0.4/1.0/2.8 1.0/2.0/40.5 mg[‡]

Key inclusion criteria

- R/R B-cell NHL after ≥1 prior regimen(s), ECOG PS 0–1
- No available therapy expected to improve survival (e.g. standard chemotherapy, autologous SCT)

Key exclusion criteria

Prior CAR-T therapy within 30 days, prior allogeneic SCT

Budde LE, et al. ASH 2018; Sehn LE, et al. ICML 2019; Shuster S et al. ASH 2019.

D, day; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; NHL, non-Hodgkin lymphoma; MCL, mantle cell lymphoma; MTD, maximum tolerated dose; R/R, relapsed/refractory; tr, transformed

Patient population


n (%)	Ν	=270*	
Median age, years (range)	62	(19–96)	
Male	172	(63.7%)	
ECOG PS 1 at baseline	164	(61.2%)†	
Aggressive NHL	180	(66.7%)	
DLBCL	117	(43.3%)	
trFL	32	(11.9%)	
MCL	23	(8.5%)	
Other	8	(3.0%)	
Indolent NHL	85	(31.5%)	
FL	82	(30.4%)	
Other	3	(1.1%)	
Median prior systemic therapies, n (range)	3	(1–14)†	
Prior CAR-T therapy	30	(11.1%)	
Prior autologous SCT	77	(28.5%)	
Refractory [‡] to last prior therapy	194	(71.9%)	
Refractory [‡] to prior anti-CD20 therapy	233	(86.3%)	

CCOD (clinical cut-off date): Aug 9, 2019; *safety evaluable pts; $^{\dagger}n=268$, as two pts did not have data entered by CCOD; $^{\pm}no$ response (PR or CR) or PD within ≤ 6 months of treatment; trFL, transformed FL;

30 pts with prior CAR-T therapy

- 17 DLBCL, 8 trFL, 5 FL
- Median 5 lines of prior systemic therapies (range 3– 14)
- 29 pts (96.7%) refractory to prior anti-CD20 therapy
- 25 pts (83.3%) refractory to last prior therapy
- 22 pts (73.3%) refractory to prior CAR-T therapy

Response rates and duration in aggressive NHL (Mosun)



17 CR pts (70.8%) remain in remission (up to 16 months off treatment)

Time on treatment and duration of response


*efficacy-evaluable pts: pts who were enrolled for at least 3 months, or had response data available at any time, or discontinued treatment for any cause; CCOD: Aug 9, 2019

Li et al. ASH 2019 P-1285; Shuster et al. ASH 2019

Mosunetuzumab use in post CAR T Nonresponders


69 yo with double expressor DLBCL

Prior therapies: RCHOP x6 (2006), RCHOP x6 + XRT (2012), Cyclophosphamide (10/2018), Axi-Cel



Mosunetuzumab in relapsed/refractory B-NHL

GO29781: a Ph1/2 open-label, multicenter study in relapsed/refractory NHL




GO29781 (Mosunetuzumab): Single-arm, Phase II expansion in patients with R/R DLBCL and >2 prior therapies (N=88)

Key inclusion criteria

- aLBCL (DLBCL, tFL, HGL)
- ECOG PS 0-1
- ≥2 prior regimens, including
 - − ≥1 anti-CD20 Ab
 - ≥ 1 anthracycline
- No requirement of CD20+

Mosunetuzumab administration

- Q3W intravenous administration
- C1 step-up dosing (CRS mitigation)
- Fixed-duration treatment
 - 8 cycles if CR after C8
 - 17 cycles if PR/SD after C8
- No mandatory hospitalization



Endpoints

- Primary: CR (best response) rate by IRF
- Secondary: ORR, DoR, PFS, safety and tolerability

Status: Completed


Bartlett et al. Blood Adv 2023

Patient population

n	N= 88
Median age, years (range)	66.5 (24–96)
Male	60 (68.2%)
ECOG PS 1 at baseline	57 (64.8%) ⁺
Aggressive NHL subtype	
DLBCL	65 (73.9%)
trFL	23 (26.1%)
Cell-of-origin	
GCB	49 (55.7%)
Non-GCB	29 (33.0%)
Unknown	10 (11.4%)
Myc and BCL2 and or BCL6 translocation	17 (19.3%)
Median prior systemic therapies, n (range)	3 (2–13) ⁺
Prior CAR-T therapy	26 (29.5%)
Prior autologous SCT	15 (17.0%)
Refractory [‡] to last prior therapy	70 (71.9%)
Refractory [‡] to prior anti-CD20 therapy	77 (87.5%)
Refractroy to prior CAR T therapy	18/26 (69.2%)


[‡]no response (PR or CR) or PD within ≤ 6 months of treatment

Adverse event overview: manageable safety profile



Mosunetuzumab monotherapy in relapsed/refractory DLBCL *GO29781: aLBCL expansion cohort*

			Outcomes	By IRF
	Response		Median time to 1st response, months (range)	1.4 (1.1-11.5)
100				· · · ·
80			Median time to first CR, months (range)	2.8 (1.1-17.5)
60	42%	24%	Duration of response; Median, months (95% CI)	7.0 (4.2-NE)
40 20		(n=21)	Duration of CR , Median, months (95% CI)	NE (9.0-NE)
0			PFS, Median, months (95% CI)	3.2 (2.2-5.3)
	ORR	CR	OS, Median, months (95% CI)	11.5 (9.0-16.4)




Relapse



GO40516: Mosunetuzumab + Polatuzumab for aggressive B-NHL

Phase Ib/II study (NCT03671018)^{5->} evaluating M-Pola combination in R/R aBNHL



1. Sun et al. Sci Transl Med 2015;7:287ra70; 2. Budde et al. J Clin Oncol 2021 [in press] 3. Sehn et al. J Clin Oncol 2020;38:155–65; 4. Tilly et al. ASCO 2019 5. NCT03671018. Available at: https://clinicaltrials.gov/; 6. Budde et al. ASH 2021

Study overview: mosunetuzumab+polatuzumab

• Phase Ib/II dose-escalation and dose-expansion study in patients with R/R B-NHL

Key inclusion criteria	Primary objectives
 DLBCL (<i>de novo</i> DLBCL, transformed FL, or Grade 3b FL): Phase Ib AND Phase II 	 Efficacy of M-Pola in patients with R/R B-NHL Safety and tolerability of M-Pola in patients with
 FL Grade 1–3a: Phase Ib only 	R/R B-NHL


M-Pola administration in Phase II expansion*

Mosunetuzumab

- Q3W intravenous infusions at RP2D (C1-8/17)⁺
- C1 step-up dosing for CRS mitigation
- No mandatory hospitalization

Polatuzumab vedotin

• Q3W intravenous infusions (1.8mg/kg) (D1 C1–6)



Baseline patient and disease characteristics

N (%) unless stated	All patients N=63	DLBCL patients N=60
Median age, years (range)	68 (20 –83)	68 (20–83)
Male	39 (61.9)	37 (61.7)
ECOG PS at entry 0-1 2	59 (93.7) 4 (6.3)	56 (93.3) 4 (6.7)
Histology DLBCL <i>de novo</i> DLBCL transformed FL Grade 3b FL FL Grade 1–3a	60 (95.2) 44 (69.8)* 12 (19.0) [†] 4 (6.3) 3 (4.8)	60 (100) 44 (73.3) 12 (20.0) 4 (6.7) 0
Bulky disease (≥10 cm)	6 (9.5)	6 (10.0)

N (%) unless stated	All patients N=63	DLBCL patients N=60
Ann Arbor stage at entry I–II III–IV	13 (20.6) 50 (79.4)	12 (20.0) 48 (80.0)
Number of prior lines of therapy 1–2 3+	24 (38.1) 39 (61.9)	24 (40.0) 36 (60.0)
Median prior lines of therapy, range	3 (1–10)	3 (1–8)
Prior CAR-T therapy	25 (39.7)	24 (40.0)
Refractory to last prior therapy	48 (76.2)	46 (76.7)

Cut-off date: March 15, 2021


*double-hit lymphoma: n=4; ⁺double-hit lymphoma: n=4; CAR-T, chimeric antigen receptor-T cell; ECOG PS, European Cooperative Oncology Group performance status

Adverse event overview: manageable safety profile

 Median time on study: 5.7 months 	range: 0.7–27.5)	AEs (≥15%) by Grade
N (%)	N=63	All AEs AEs related to treatme
Grade 5 (fatal) AE* M-Pola related	3 (4.8) [†] 1 (1.6)	Diarrhea Neutropenia [‡] - Nausea - Decreased appetite -
AE leading to M discontinuation M related	5 (7.9) 3 (4.8)	Headache - Pyrexia - Chills -
AE leading to Pola discontinuation Pola related	8 (12.7) 6 (9.5)	Hypophosphatemia - Peripheral sensory neuropathy - Abdominal pain - Constipation
CRS (any Grade)* Grade 1	11 (17.5) 10 (15.9)	Cytokine release syndrome - Dry skin - Insomnia - Edema peripheral -
Grade 2	1 (1.6)	Rash Dizziness
Grade 3	0	100 80 60 40 20 0 20 40 60 80 Frequency (%)
ICANS any grade Grade 3-4	5 (7.9) 2 (3.2)	 The majority of AEs were low Grade;
	1	all CRS & NT resolved.

*excluding 9 Grade 5 AEs of PD; [†]treatment-related: pneumonia (1 patient); treatment-unrelated: respiratory failure and sudden cardiac death (1 patient each); [‡]grouped term including Preferred Term 'neutropenia' and 'neutrophil count decreased'; AE, adverse event;


Anti-tumor efficacy: Mosun + Pola



Budde et al. ASH 2021

Response in DLBCL patients*

• Median duration of response in all DLBCL patients: NR (95% CI: 6.3, NE)




- Median PFS: 8.9 months (95% CI: 3.5, NE)
- PFS data are immature
- Of 29 patients who achieved CR, 28 (96.6%) remained in CR and 1 (3.4%) had PD
 - the patient with PD subsequently received retreatment and achieved a CR
- Phase 2 pivotal cohort completed

Response assessed by investigators using Lugano 2014 criteria¹; CI, confidence interval; NR, not reached

Budde et al. ASH 2021

SUNMO (NCT05171647) a randomized, open-label, multicenter, global Phase III trial




(relapsed vs refractory)

Mosunetuzumab: 1st line DLBCL

GO40554 (NCT03677154): an ongoing Phase 1

elderly/unfit frontline use of single agent Mosunetuzumab in elderly/unfit pts with newly diagnosed DLBCL



Olszewski et al. ASH 2020

Mosunetuzumab in relapsed/refractory DLBCL

	Regimens
First line	Mosun or Mosun+pola (NCT03677154): Elderly unfit (NCT05207670) Mosun + CHOP or CHP-pola (NCT03677141)
Second line	Mosun+platinum based chemo (DHAX or ICE) NCT05464329: Transplant eligible Mosun monotherapy (NCT05412290): Post transplant consolidation
Third line	Mosun+pola (NCT03671018, phase II); NCT05171647 (phase III) Mosun+ lonca-T (NCT05672251) Mosun+pola + CAR T (NCT05260957) CAR T (PR+SD), randomized to Mosun, pola, M+P, or SOC (SWOG, NCT05633615) CAR T followed by Mosun (NCT04889716) Mosun+ CELMoDs (NCT05169515) Mosun+pola+tafasitmab+lenalidomide (NCT05615636) Mosun+atezolizumab (NCT02500407, terminated) Mosun + tiragolumab (NCT05315713) Mosun_GemOX (NCT04313608)

Conclusions

- Mosunetuzumab leads to meaningful remissions in B cell lymphomas.
- Mosunetuzumab is expanding its clinical development in earlier line use and in combinational
- use for aBCL. favorable attributes (outpatient use, fixed treatment duration, and favorable safety profile)
- Understanding the mechanism of action, mechanism of resistance, evolution of tumor and its microenvironment are essential to guide the rational design of therapeutic regimens using BsAbs.













